AbbVie eyes extended Qulipta use case on Phase III menstrual migraine win
There are currently no targeted therapies specifically approved for menstrual migraine, though other anti-migraine drugs are used off-label in this indication.
Neurology
Biohaven’s epilepsy drug hit with FDA clinical hold
Narcolepsy market expected to reach $7.8bn across 7MM by 2035
Podcast: Bringing diversity to Alzheimer’s trials
Loneliness interventions do not have strong sustained effects on memory function
NeuroSense’s ALS drug cuts key biomarker in Phase IIb trial
Auvelity becomes first non-antipsychotic approved for Alzheimer’s agitation
AAN 2026: New data demonstrates Symbravo’s cumulative benefit for acute migraine
